ISTCT unit « Imaging and therapeutical strategies in cerebral and tumoral pathologies » is a research unit created in 2012 (Dir. Myriam Bernaudin) with the CNRS, the  CEA and the University of Caen Normandie (UNICAEN) hosted at the GIP CYCERON in Caen.

ISTCT is interested in certain physiopathological mechanisms in oncology and neurology, and aims at developing innovative therapeutic strategies or biomedical imaging, in particular by the development and the validation of new radiopharmaceuticals, for tumoral and cerebral pathologies (brain tumours, lymphomas, brain hypoxia/ischaemia…). ISTCT conducts fundamental, preclinical and clinical researches, and associates multidisciplinary works in chemistry, radiochemistry and biology.

This unity includes about fifty people associating clinicians, researchers/assistant-professors, technicians/engineers and students of various horizons (chemistry, radiochemistry, biology, medicine, pharmacy, physiopathology, biomedical imaging), favouring the development of transverse and translational researches. The unit consists of two teams of complementary expertises:

The CERVOxy team " Hypoxia, cerebrovascular and tumoral pathophysiologies " (Resp. Myriam BERNAUDIN and Samuel VALABLE) leads researches in particular in the field of the hypoxia/ischaemia and the brain tumours (glioblastoma, cerebral metastasis). This team combines approaches in multimodal imaging (MRI, PET, multiphoton imaging) and in therapeutic strategies including molecular, cellular therapies, nanoparticles as well as the radiotherapy of which the hadrontherapy (in connection with the ARCHADE program, by using and/or by developing relevant preclinical models towards the clinic.


The LDM-TEP team "Laboratory of Methodological Development in Tomography by Emission of Positrons" (Resp. Cécile Perrio) develop radiopharmaceuticals intended in the preclinical and clinical research for the Positrons Emission Tomography (PET). This team combines methodological and applied researches in radiochemistry (carbon 11, fluorine 18, gallium 68), radiopharmaceutical radiolabelling, and in vitro evaluation by techniques of autoradiography and in vivo by PET imaging (metabolism, pharmacokinetics, affinity, specificity …) in pathological animal models. The LDM-TEP assures, in accordance with the regulations, the preparation of the radiopharmaceutical ones   for clinical trials.